Buparlisib is a brain penetrable pan-PI3K inhibitor
2018 · Scientific Reports · 80 citations
https://doi.org/10.1038/s41598-018-29062-w
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
14
Papers
438
Citations
6
h-index
6
i10-index
Nishita Thota is an academic researcher. The author has contributed to research in topics: PI3K/AKT/mTOR signaling in cancer & Cancer Genomics and Diagnostics & MicroRNA in disease regulation. The author has an h-index of 6, co-authored 12 publications.
ORCID: 0000-0003-3529-9455https://doi.org/10.1038/s41598-018-29062-w
https://doi.org/10.1038/s41467-024-55428-y
Click to start Chat